Lexicon Pharmaceuticals to present at H.C. Wainwright BioConnect conference on May 19, 2026

Lexicon Pharmaceuticals announced that its management will participate in a fireside chat at the 4th Annual H.C. Wainwright BioConnect Investor Conference on May 19, 2026, at Nasdaq World Headquarters in New York City. The event will be available live and as a replay on the company's website. Lexicon is a biopharmaceutical company focused on developing treatments for neuropathic pain, hypertrophic cardiomyopathy, obesity, metabolic disorders, and other cardiometabolic conditions. This presentation offers investors insight into the company's pipeline and strategic direction.